Waiv, developer of an AI precision testing platform, is spinning out of AI biotech Owkin with a $33 million Series A, CEO Meriem Sefta tells Axios Pro exclusively.
What's next: Sefta says Waiv is currently in discussions with multiple pharma companies about new collaborations focused on AI-enabled pathology tests.
